悪性中皮腫治療薬の世界市場（～2026年）

• 英文タイトル：Global Malignant Mesothelioma Drugs Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY12583 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、130ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は悪性中皮腫治療薬のグローバル市場について調査・分析したレポートです。種類別（ペメトレキセド、シスプラチン、カルボプラチン、ゲムシタビン、ビノレルビン、その他）市場規模、用途別（病院薬局、小売薬局、腫瘍センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別悪性中皮腫治療薬の競争状況、市場シェア ・世界の悪性中皮腫治療薬市場：種類別市場規模 2015年-2020年（ペメトレキセド、シスプラチン、カルボプラチン、ゲムシタビン、ビノレルビン、その他） ・世界の悪性中皮腫治療薬市場：種類別市場規模予測 2021年-2026年（ペメトレキセド、シスプラチン、カルボプラチン、ゲムシタビン、ビノレルビン、その他） ・世界の悪性中皮腫治療薬市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、腫瘍センター、その他） ・世界の悪性中皮腫治療薬市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、腫瘍センター、その他） ・北米の悪性中皮腫治療薬市場分析：米国、カナダ ・ヨーロッパの悪性中皮腫治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの悪性中皮腫治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の悪性中皮腫治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの悪性中皮腫治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca、Bristol-Myers Squibb、Roche、Merck、Novartis、Pfizer、Sanofi、Eli Lilly、Teva Pharmaceuticals、Boehringer Ingelheim GmbH、Mylan、Fresenius Kabi、Sun Pharmaceuticals、Corden Pharma、Concordia International、Kyowa Hakko Kirin、Polaris Pharmaceuticals、MolMed、Ono Pharmaceutical、Nichi-Iko Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of mesothelioma drugs by governments to ensure availability in hospital pharmacies and oncology centers.

Market Analysis and Insights: Global Malignant Mesothelioma Drugs Market
The global Malignant Mesothelioma Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Malignant Mesothelioma Drugs Scope and Market Size
Malignant Mesothelioma Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Malignant Mesothelioma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
AstraZeneca
Bristol-Myers Squibb
Roche
Merck
Novartis
Pfizer
Sanofi
Eli Lilly
Teva Pharmaceuticals
Boehringer Ingelheim GmbH
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Corden Pharma
Concordia International
Kyowa Hakko Kirin
Polaris Pharmaceuticals
MolMed
Ono Pharmaceutical
Nichi-Iko Pharmaceutical

Market segment by Type, the product can be split into
Pemetrexed
Cisplatin
Carboplatin
Gemcitabine
Vinorelbine
Other
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Oncology Centers
Other

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Malignant Mesothelioma Drugs Revenue
1.4 Market by Type
1.4.1 Global Malignant Mesothelioma Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Pemetrexed
1.4.3 Cisplatin
1.4.4 Carboplatin
1.4.5 Gemcitabine
1.4.6 Vinorelbine
1.4.7 Other
1.5 Market by Application
1.5.1 Global Malignant Mesothelioma Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Oncology Centers
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Malignant Mesothelioma Drugs Market Perspective (2015-2026)
2.2 Global Malignant Mesothelioma Drugs Growth Trends by Regions
2.2.1 Malignant Mesothelioma Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Malignant Mesothelioma Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Malignant Mesothelioma Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Malignant Mesothelioma Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Malignant Mesothelioma Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Malignant Mesothelioma Drugs Players by Market Size
3.1.1 Global Top Malignant Mesothelioma Drugs Players by Revenue (2015-2020)
3.1.2 Global Malignant Mesothelioma Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Malignant Mesothelioma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Malignant Mesothelioma Drugs Market Concentration Ratio
3.2.1 Global Malignant Mesothelioma Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Drugs Revenue in 2019
3.3 Malignant Mesothelioma Drugs Key Players Head office and Area Served
3.4 Key Players Malignant Mesothelioma Drugs Product Solution and Service
3.5 Date of Enter into Malignant Mesothelioma Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Malignant Mesothelioma Drugs Historic Market Size by Type (2015-2020)
4.2 Global Malignant Mesothelioma Drugs Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Malignant Mesothelioma Drugs Market Size by Application (2015-2020)
5.2 Global Malignant Mesothelioma Drugs Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Malignant Mesothelioma Drugs Market Size (2015-2020)
6.2 Malignant Mesothelioma Drugs Key Players in North America (2019-2020)
6.3 North America Malignant Mesothelioma Drugs Market Size by Type (2015-2020)
6.4 North America Malignant Mesothelioma Drugs Market Size by Application (2015-2020)

7 Europe
7.1 Europe Malignant Mesothelioma Drugs Market Size (2015-2020)
7.2 Malignant Mesothelioma Drugs Key Players in Europe (2019-2020)
7.3 Europe Malignant Mesothelioma Drugs Market Size by Type (2015-2020)
7.4 Europe Malignant Mesothelioma Drugs Market Size by Application (2015-2020)

8 China
8.1 China Malignant Mesothelioma Drugs Market Size (2015-2020)
8.2 Malignant Mesothelioma Drugs Key Players in China (2019-2020)
8.3 China Malignant Mesothelioma Drugs Market Size by Type (2015-2020)
8.4 China Malignant Mesothelioma Drugs Market Size by Application (2015-2020)

9 Japan
9.1 Japan Malignant Mesothelioma Drugs Market Size (2015-2020)
9.2 Malignant Mesothelioma Drugs Key Players in Japan (2019-2020)
9.3 Japan Malignant Mesothelioma Drugs Market Size by Type (2015-2020)
9.4 Japan Malignant Mesothelioma Drugs Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Malignant Mesothelioma Drugs Market Size (2015-2020)
10.2 Malignant Mesothelioma Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Malignant Mesothelioma Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Malignant Mesothelioma Drugs Market Size by Application (2015-2020)

11 India
11.1 India Malignant Mesothelioma Drugs Market Size (2015-2020)
11.2 Malignant Mesothelioma Drugs Key Players in India (2019-2020)
11.3 India Malignant Mesothelioma Drugs Market Size by Type (2015-2020)
11.4 India Malignant Mesothelioma Drugs Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Malignant Mesothelioma Drugs Market Size (2015-2020)
12.2 Malignant Mesothelioma Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Malignant Mesothelioma Drugs Market Size by Type (2015-2020)
12.4 Central & South America Malignant Mesothelioma Drugs Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 AstraZeneca
13.1.1 AstraZeneca Company Details
13.1.2 AstraZeneca Business Overview
13.1.3 AstraZeneca Malignant Mesothelioma Drugs Introduction
13.1.4 AstraZeneca Revenue in Malignant Mesothelioma Drugs Business (2015-2020))
13.1.5 AstraZeneca Recent Development
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Details
13.2.2 Bristol-Myers Squibb Business Overview
13.2.3 Bristol-Myers Squibb Malignant Mesothelioma Drugs Introduction
13.2.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
13.2.5 Bristol-Myers Squibb Recent Development
13.3 Roche
13.3.1 Roche Company Details
13.3.2 Roche Business Overview
13.3.3 Roche Malignant Mesothelioma Drugs Introduction
13.3.4 Roche Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
13.3.5 Roche Recent Development
13.4 Merck
13.4.1 Merck Company Details
13.4.2 Merck Business Overview
13.4.3 Merck Malignant Mesothelioma Drugs Introduction
13.4.4 Merck Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
13.4.5 Merck Recent Development
13.5 Novartis
13.5.1 Novartis Company Details
13.5.2 Novartis Business Overview
13.5.3 Novartis Malignant Mesothelioma Drugs Introduction
13.5.4 Novartis Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
13.5.5 Novartis Recent Development
13.6 Pfizer
13.6.1 Pfizer Company Details
13.6.2 Pfizer Business Overview
13.6.3 Pfizer Malignant Mesothelioma Drugs Introduction
13.6.4 Pfizer Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
13.6.5 Pfizer Recent Development
13.7 Sanofi
13.7.1 Sanofi Company Details
13.7.2 Sanofi Business Overview
13.7.3 Sanofi Malignant Mesothelioma Drugs Introduction
13.7.4 Sanofi Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
13.7.5 Sanofi Recent Development
13.8 Eli Lilly
13.8.1 Eli Lilly Company Details
13.8.2 Eli Lilly Business Overview
13.8.3 Eli Lilly Malignant Mesothelioma Drugs Introduction
13.8.4 Eli Lilly Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
13.8.5 Eli Lilly Recent Development
13.9 Teva Pharmaceuticals
13.9.1 Teva Pharmaceuticals Company Details
13.9.2 Teva Pharmaceuticals Business Overview
13.9.3 Teva Pharmaceuticals Malignant Mesothelioma Drugs Introduction
13.9.4 Teva Pharmaceuticals Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
13.9.5 Teva Pharmaceuticals Recent Development
13.10 Boehringer Ingelheim GmbH
13.10.1 Boehringer Ingelheim GmbH Company Details
13.10.2 Boehringer Ingelheim GmbH Business Overview
13.10.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Introduction
13.10.4 Boehringer Ingelheim GmbH Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
13.10.5 Boehringer Ingelheim GmbH Recent Development
13.11 Mylan
10.11.1 Mylan Company Details
10.11.2 Mylan Business Overview
10.11.3 Mylan Malignant Mesothelioma Drugs Introduction
10.11.4 Mylan Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
10.11.5 Mylan Recent Development
13.12 Fresenius Kabi
10.12.1 Fresenius Kabi Company Details
10.12.2 Fresenius Kabi Business Overview
10.12.3 Fresenius Kabi Malignant Mesothelioma Drugs Introduction
10.12.4 Fresenius Kabi Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
10.12.5 Fresenius Kabi Recent Development
13.13 Sun Pharmaceuticals
10.13.1 Sun Pharmaceuticals Company Details
10.13.2 Sun Pharmaceuticals Business Overview
10.13.3 Sun Pharmaceuticals Malignant Mesothelioma Drugs Introduction
10.13.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
10.13.5 Sun Pharmaceuticals Recent Development
13.14 Corden Pharma
10.14.1 Corden Pharma Company Details
10.14.2 Corden Pharma Business Overview
10.14.3 Corden Pharma Malignant Mesothelioma Drugs Introduction
10.14.4 Corden Pharma Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
10.14.5 Corden Pharma Recent Development
13.15 Concordia International
10.15.1 Concordia International Company Details
10.15.2 Concordia International Business Overview
10.15.3 Concordia International Malignant Mesothelioma Drugs Introduction
10.15.4 Concordia International Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
10.15.5 Concordia International Recent Development
13.16 Kyowa Hakko Kirin
10.16.1 Kyowa Hakko Kirin Company Details
10.16.2 Kyowa Hakko Kirin Business Overview
10.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Introduction
10.16.4 Kyowa Hakko Kirin Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
10.16.5 Kyowa Hakko Kirin Recent Development
13.17 Polaris Pharmaceuticals
10.17.1 Polaris Pharmaceuticals Company Details
10.17.2 Polaris Pharmaceuticals Business Overview
10.17.3 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Introduction
10.17.4 Polaris Pharmaceuticals Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
10.17.5 Polaris Pharmaceuticals Recent Development
13.18 MolMed
10.18.1 MolMed Company Details
10.18.2 MolMed Business Overview
10.18.3 MolMed Malignant Mesothelioma Drugs Introduction
10.18.4 MolMed Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
10.18.5 MolMed Recent Development
13.19 Ono Pharmaceutical
10.19.1 Ono Pharmaceutical Company Details
10.19.2 Ono Pharmaceutical Business Overview
10.19.3 Ono Pharmaceutical Malignant Mesothelioma Drugs Introduction
10.19.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
10.19.5 Ono Pharmaceutical Recent Development
13.20 Nichi-Iko Pharmaceutical
10.20.1 Nichi-Iko Pharmaceutical Company Details
10.20.2 Nichi-Iko Pharmaceutical Business Overview
10.20.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Introduction
10.20.4 Nichi-Iko Pharmaceutical Revenue in Malignant Mesothelioma Drugs Business (2015-2020)
10.20.5 Nichi-Iko Pharmaceutical Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Malignant Mesothelioma Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Malignant Mesothelioma Drugs Revenue
Table 3. Ranking of Global Top Malignant Mesothelioma Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Malignant Mesothelioma Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Pemetrexed
Table 6. Key Players of Cisplatin
Table 7. Key Players of Carboplatin
Table 8. Key Players of Gemcitabine
Table 9. Key Players of Vinorelbine
Table 10. Key Players of Other
Table 11. Global Malignant Mesothelioma Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 12. Global Malignant Mesothelioma Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 13. Global Malignant Mesothelioma Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 14. Global Malignant Mesothelioma Drugs Market Share by Regions (2015-2020)
Table 15. Global Malignant Mesothelioma Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 16. Global Malignant Mesothelioma Drugs Market Share by Regions (2021-2026)
Table 17. Market Top Trends
Table 18. Key Drivers: Impact Analysis
Table 19. Key Challenges
Table 20. Malignant Mesothelioma Drugs Market Growth Strategy
Table 21. Main Points Interviewed from Key Malignant Mesothelioma Drugs Players
Table 22. Global Malignant Mesothelioma Drugs Revenue by Players (2015-2020) (Million US$)
Table 23. Global Malignant Mesothelioma Drugs Market Share by Players (2015-2020)
Table 24. Global Top Malignant Mesothelioma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Mesothelioma Drugs as of 2019)
Table 25. Global Malignant Mesothelioma Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Malignant Mesothelioma Drugs Product Solution and Service
Table 28. Date of Enter into Malignant Mesothelioma Drugs Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Malignant Mesothelioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 31. Global Malignant Mesothelioma Drugs Market Size Share by Type (2015-2020)
Table 32. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2021-2026)
Table 33. Global Malignant Mesothelioma Drugs Market Size Share by Application (2015-2020)
Table 34. Global Malignant Mesothelioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 35. Global Malignant Mesothelioma Drugs Market Size Share by Application (2021-2026)
Table 36. North America Key Players Malignant Mesothelioma Drugs Revenue (2019-2020) (Million US$)
Table 37. North America Key Players Malignant Mesothelioma Drugs Market Share (2019-2020)
Table 38. North America Malignant Mesothelioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 39. North America Malignant Mesothelioma Drugs Market Share by Type (2015-2020)
Table 40. North America Malignant Mesothelioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 41. North America Malignant Mesothelioma Drugs Market Share by Application (2015-2020)
Table 42. Europe Key Players Malignant Mesothelioma Drugs Revenue (2019-2020) (Million US$)
Table 43. Europe Key Players Malignant Mesothelioma Drugs Market Share (2019-2020)
Table 44. Europe Malignant Mesothelioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 45. Europe Malignant Mesothelioma Drugs Market Share by Type (2015-2020)
Table 46. Europe Malignant Mesothelioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 47. Europe Malignant Mesothelioma Drugs Market Share by Application (2015-2020)
Table 48. China Key Players Malignant Mesothelioma Drugs Revenue (2019-2020) (Million US$)
Table 49. China Key Players Malignant Mesothelioma Drugs Market Share (2019-2020)
Table 50. China Malignant Mesothelioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 51. China Malignant Mesothelioma Drugs Market Share by Type (2015-2020)
Table 52. China Malignant Mesothelioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 53. China Malignant Mesothelioma Drugs Market Share by Application (2015-2020)
Table 54. Japan Key Players Malignant Mesothelioma Drugs Revenue (2019-2020) (Million US$)
Table 55. Japan Key Players Malignant Mesothelioma Drugs Market Share (2019-2020)
Table 56. Japan Malignant Mesothelioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 57. Japan Malignant Mesothelioma Drugs Market Share by Type (2015-2020)
Table 58. Japan Malignant Mesothelioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 59. Japan Malignant Mesothelioma Drugs Market Share by Application (2015-2020)
Table 60. Southeast Asia Key Players Malignant Mesothelioma Drugs Revenue (2019-2020) (Million US$)
Table 61. Southeast Asia Key Players Malignant Mesothelioma Drugs Market Share (2019-2020)
Table 62. Southeast Asia Malignant Mesothelioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 63. Southeast Asia Malignant Mesothelioma Drugs Market Share by Type (2015-2020)
Table 64. Southeast Asia Malignant Mesothelioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 65. Southeast Asia Malignant Mesothelioma Drugs Market Share by Application (2015-2020)
Table 66. India Key Players Malignant Mesothelioma Drugs Revenue (2019-2020) (Million US$)
Table 67. India Key Players Malignant Mesothelioma Drugs Market Share (2019-2020)
Table 68. India Malignant Mesothelioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 69. India Malignant Mesothelioma Drugs Market Share by Type (2015-2020)
Table 70. India Malignant Mesothelioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 71. India Malignant Mesothelioma Drugs Market Share by Application (2015-2020)
Table 72. Central & South America Key Players Malignant Mesothelioma Drugs Revenue (2019-2020) (Million US$)
Table 73. Central & South America Key Players Malignant Mesothelioma Drugs Market Share (2019-2020)
Table 74. Central & South America Malignant Mesothelioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 75. Central & South America Malignant Mesothelioma Drugs Market Share by Type (2015-2020)
Table 76. Central & South America Malignant Mesothelioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 77. Central & South America Malignant Mesothelioma Drugs Market Share by Application (2015-2020)
Table 78. AstraZeneca Company Details
Table 79. AstraZeneca Business Overview
Table 80. AstraZeneca Product
Table 81. AstraZeneca Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 82. AstraZeneca Recent Development
Table 83. Bristol-Myers Squibb Company Details
Table 84. Bristol-Myers Squibb Business Overview
Table 85. Bristol-Myers Squibb Product
Table 86. Bristol-Myers Squibb Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 87. Bristol-Myers Squibb Recent Development
Table 88. Roche Company Details
Table 89. Roche Business Overview
Table 90. Roche Product
Table 91. Roche Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 92. Roche Recent Development
Table 93. Merck Company Details
Table 94. Merck Business Overview
Table 95. Merck Product
Table 96. Merck Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 97. Merck Recent Development
Table 98. Novartis Company Details
Table 99. Novartis Business Overview
Table 100. Novartis Product
Table 101. Novartis Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 102. Novartis Recent Development
Table 103. Pfizer Company Details
Table 104. Pfizer Business Overview
Table 105. Pfizer Product
Table 106. Pfizer Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 107. Pfizer Recent Development
Table 108. Sanofi Company Details
Table 109. Sanofi Business Overview
Table 110. Sanofi Product
Table 111. Sanofi Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 112. Sanofi Recent Development
Table 113. Eli Lilly Business Overview
Table 114. Eli Lilly Product
Table 115. Eli Lilly Company Details
Table 116. Eli Lilly Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 117. Eli Lilly Recent Development
Table 118. Teva Pharmaceuticals Company Details
Table 119. Teva Pharmaceuticals Business Overview
Table 120. Teva Pharmaceuticals Product
Table 121. Teva Pharmaceuticals Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 122. Teva Pharmaceuticals Recent Development
Table 123. Boehringer Ingelheim GmbH Company Details
Table 124. Boehringer Ingelheim GmbH Business Overview
Table 125. Boehringer Ingelheim GmbH Product
Table 126. Boehringer Ingelheim GmbH Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 127. Boehringer Ingelheim GmbH Recent Development
Table 128. Mylan Company Details
Table 129. Mylan Business Overview
Table 130. Mylan Product
Table 131. Mylan Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 132. Mylan Recent Development
Table 133. Fresenius Kabi Company Details
Table 134. Fresenius Kabi Business Overview
Table 135. Fresenius Kabi Product
Table 136. Fresenius Kabi Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 137. Fresenius Kabi Recent Development
Table 138. Sun Pharmaceuticals Company Details
Table 139. Sun Pharmaceuticals Business Overview
Table 140. Sun Pharmaceuticals Product
Table 141. Sun Pharmaceuticals Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 142. Sun Pharmaceuticals Recent Development
Table 143. Corden Pharma Company Details
Table 144. Corden Pharma Business Overview
Table 145. Corden Pharma Product
Table 146. Corden Pharma Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 147. Corden Pharma Recent Development
Table 148. Concordia International Company Details
Table 149. Concordia International Business Overview
Table 150. Concordia International Product
Table 151. Concordia International Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 152. Concordia International Recent Development
Table 153. Kyowa Hakko Kirin Company Details
Table 154. Kyowa Hakko Kirin Business Overview
Table 155. Kyowa Hakko Kirin Product
Table 156. Kyowa Hakko Kirin Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 157. Kyowa Hakko Kirin Recent Development
Table 158. Polaris Pharmaceuticals Company Details
Table 159. Polaris Pharmaceuticals Business Overview
Table 160. Polaris Pharmaceuticals Product
Table 161. Polaris Pharmaceuticals Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 162. Polaris Pharmaceuticals Recent Development
Table 163. MolMed Company Details
Table 164. MolMed Business Overview
Table 165. MolMed Product
Table 166. MolMed Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 167. MolMed Recent Development
Table 168. Ono Pharmaceutical Company Details
Table 169. Ono Pharmaceutical Business Overview
Table 170. Ono Pharmaceutical Product
Table 171. Ono Pharmaceutical Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 172. Ono Pharmaceutical Recent Development
Table 173. Nichi-Iko Pharmaceutical Company Details
Table 174. Nichi-Iko Pharmaceutical Business Overview
Table 175. Nichi-Iko Pharmaceutical Product
Table 176. Nichi-Iko Pharmaceutical Revenue in Malignant Mesothelioma Drugs Business (2015-2020) (Million US$)
Table 177. Nichi-Iko Pharmaceutical Recent Development
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Malignant Mesothelioma Drugs Market Share by Type: 2020 VS 2026
Figure 2. Pemetrexed Features
Figure 3. Cisplatin Features
Figure 4. Carboplatin Features
Figure 5. Gemcitabine Features
Figure 6. Vinorelbine Features
Figure 7. Other Features
Figure 8. Global Malignant Mesothelioma Drugs Market Share by Application: 2020 VS 2026
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Oncology Centers Case Studies
Figure 12. Other Case Studies
Figure 13. Malignant Mesothelioma Drugs Report Years Considered
Figure 14. Global Malignant Mesothelioma Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Malignant Mesothelioma Drugs Market Share by Regions: 2020 VS 2026
Figure 16. Global Malignant Mesothelioma Drugs Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Malignant Mesothelioma Drugs Market Share by Players in 2019
Figure 19. Global Top Malignant Mesothelioma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Mesothelioma Drugs as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Malignant Mesothelioma Drugs Revenue in 2019
Figure 21. North America Malignant Mesothelioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Malignant Mesothelioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Malignant Mesothelioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Malignant Mesothelioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Malignant Mesothelioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Malignant Mesothelioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Malignant Mesothelioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Bottom-up and Top-down Approaches for This Report
Figure 29. Data Triangulation
Figure 30. Key Executives Interviewed

---